GABAB PAM for the treatment of pain and CMT1A

Our license agreement with Indivior provides for a funded research program, under which we have the right to select drug candidates for exclusive development in certain indications outside of substance use disorder. 

We plan to develop our selected centrally active drug candidate in pain and peripherally restricted GABAB PAM in bladder pain and CMT1A. These indications have been validated with baclofen, an orthosteric agonist of GABAB and present a significant unmet medical need and commercial opportunity. 

We are in clinical candidate selection phase and expect IND enabling studies to be initiated in the first quarter of 2023.